Business
Scancell to produce TCB antibodies
Scancell to produce TCB antibodies.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n 23 June 2022\n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n \n Scancell to produce and clinically validate T cell redirecting bispecific antibodies\n \n \n \n \n \n \n \n Company to combine proprietary GlyMab® antibodies with in-licenced Fc silencing technology from mAbsolve\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces it will develop GlyMab® antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. This is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity which crosslinks tumour cells via their glycans with an activating receptor CD3 on T cells. This results in activation of killer T cells and tumour cell death. These antibodies are particularly potent in tumours which have lost the T cell recognition molecule major histocompatibility antigen (MHC) or where there is limited T cell infiltration as they by-pass normal T cell activation pathways and redirect the host immune system to the tumour.\n The Company is currently in the preclinical research phase and expects to take this novel product into a Phase 1 clinical study in due course. The Board believes this will provide a strong validation and demonstration of value for the whole GlyMab® antibody platform.\n \n \n \n \n \n To create TCB antibodies, Scancell will combine its proprietary GlyMab® antibodies, which target sugar motifs rather than proteins and are designed to have superior affinity and selectivity profiles, with in-licenced Fc silencing technology from Oxford-based mAbsolve. The technology from mAbsolve\n reduces the likelihood of\n toxicity caused by cytokine storms, which can be associated with clinical antibodies engaging the immune system. Scancell will leverage its deep understanding of cancer immunotherapy and T cell immunology together with its strong development capabilities to bring the TCB antibodies to clinical validation, thereby adding value to the entire GlyMab® platform.\n \n \n \n \n \n In parallel, the Company will utilise the GlyMab® platform to deliver cytotoxic drugs (ADC) or cell therapies (CAR). The Boar...